Structure Therapeutics Inc.
21.19USD
-0.7400 (-3.37%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on GPCR.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.24▼ | -$0.19 | 0 | 1 |
| Next quarter | -$0.49▼ | -$0.45 | 0 | 1 |
| Current year | -$1.62▼ | -$1.43 | 0 | 2 |
| Next year | -$2.19▼ | -$2.08 | 1 | 2 |
Beat in 1 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.38 | -$0.49 | -0.11 (-28.3%) |
| 2026-03-31 | -$0.31 | -$0.35 | -0.04 (-12.9%) |
| 2025-12-31 | -$0.37 | $0.2 | +0.57 (+154.2%) |
| 2025-09-30 | -$0.37 | -$0.37 | -0.00 (-0.6%) |
61 ratings from 16 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Citizens | Reiterated | Market Outperform | $110 | Sep 9, 2026 |
| Citigroup | Maintained | Buy | $100 $97 | Aug 7, 2026 |
| Citizens | Maintained | Market Outperform | $113 $110 | Aug 7, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $100 $70 | Jun 11, 2026 |
| Canaccord Genuity | Initiated | Buy | $101 | Apr 27, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $114 $100 | Mar 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $90 $114 | Mar 2, 2026 |
| Citizens | Maintained | Market Outperform | $120 $113 | Feb 27, 2026 |
| JP Morgan | Maintained | Overweight | $65 $105 | Jan 22, 2026 |
| Guggenheim | Maintained | Buy | $90 $140 | Jan 20, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $60 $90 | Dec 19, 2025 |
| Morgan Stanley | Maintained | Overweight | $120 $125 | Dec 12, 2025 |
| Citizens | Maintained | Market Outperform | $87 $120 | Dec 12, 2025 |
| Jefferies | Maintained | Buy | $79 $125 | Dec 11, 2025 |
| Citigroup | Maintained | Buy | $60 $100 | Dec 9, 2025 |
| Stifel | Maintained | Buy | $50 $90 | Dec 9, 2025 |
| Clear Street | Maintained | Buy | $61 $99 | Dec 9, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $75 $60 | Aug 7, 2025 |
| Guggenheim | Maintained | Buy | $92 $90 | Aug 7, 2025 |
| JMP Securities | Maintained | Market Outperform | $89 $87 | Aug 7, 2025 |
| Cantor Fitzgerald | Reiterated | Overweight | $65 | Jun 23, 2025 |
| JMP Securities | Reiterated | Market Outperform | $89 | Jun 23, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $80 $75 | May 12, 2025 |
| Citigroup | Initiated | Buy | $60 | May 2, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $80 | Apr 22, 2025 |
29 filings from 9 insiders · 0 buy / 0 sell over 6m
Officers and directors of GPCR, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Coll Crespo BlasOfficer, CHIEF MEDICAL OFFICER | SellAmerican Depositary Shares | 4.0k | $36.15 | $145k | Sep 21, 2026 |
| Coll Crespo BlasOfficer, CHIEF MEDICAL OFFICER | Exercise | 12.0k | — | — | Sep 21, 2026 |
| Coll Crespo BlasOfficer, CHIEF MEDICAL OFFICER | ExerciseAmerican Depositary Shares | 4.0k | — | — | Sep 21, 2026 |
| Coll Crespo BlasOfficer, CHIEF MEDICAL OFFICER | Tax | 10.6k | $11.67 | $124k | Sep 18, 2026 |
| LIN XICHENOfficer | Exercise | 17.8k | $0.34 | $6k | Sep 1, 2026 |
| LIN XICHENOfficer | Exercise | 11.8k | $0.34 | $4k | Aug 18, 2026 |
| BERRIOS JOHN JOSEPHOfficer | Grant | 140.8k | — | — | Aug 6, 2026 |
| LIN XICHENOfficer | Exercise | 11.8k | $0.34 | $4k | Aug 4, 2026 |
| LIN XICHENOfficer | Exercise | 23.6k | $50.59 | $1.20M | Jul 14, 2026 |
| LIN XICHENOfficer | Exercise | 23.6k | $0.34 | $8k | Jun 25, 2026 |
| LANG MATTHEWChief Operating Officer | Grant | 184.6k | — | — | Apr 15, 2026 |
| STEVENS RAYMOND CChief Executive Officer | Grant | 260.2k | — | — | Mar 19, 2026 |
| HALL ASHLEYOfficer | Grant | 47.7k | — | — | Mar 19, 2026 |
| MA YINGLIChief Technology Officer | Grant | 32.5k | — | — | Mar 19, 2026 |
| LIN XICHENOfficer | Grant | 43.4k | — | — | Mar 19, 2026 |
| YOON JUNChief Financial Officer | Grant | 104.1k | — | — | Mar 19, 2026 |
| COLL CRESPO BLASOfficer | Grant | 75.9k | — | — | Mar 19, 2026 |
| STEVENS RAYMOND CChief Executive Officer | Grant | 89.7k | — | — | Jul 1, 2025 |
| MA YINGLIChief Technology Officer | Grant | 24.5k | — | — | Jul 1, 2025 |
| LIN XICHENOfficer | Grant | 57.1k | — | — | Jul 1, 2025 |
No analyst notes on GPCR yet.
Analyst Ratings
14 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 4 | 11 | 1 | 0 | 0 | Buy1.81 |
| 1 mo ago | 4 | 11 | 1 | 0 | 0 | Buy1.81 |
| 2 mo ago | 4 | 11 | 1 | 0 | 0 | Buy1.81 |
| 3 mo ago | 4 | 11 | 1 | 0 | 0 | Buy1.81 |
Members whose judged calls on GPCR have played out most reliably.
No settled calls on GPCR yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice